SG11202106344SA - Deutetrabenazine for the treatment of dyskinesia in cerebral palsy - Google Patents

Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Info

Publication number
SG11202106344SA
SG11202106344SA SG11202106344SA SG11202106344SA SG11202106344SA SG 11202106344S A SG11202106344S A SG 11202106344SA SG 11202106344S A SG11202106344S A SG 11202106344SA SG 11202106344S A SG11202106344S A SG 11202106344SA SG 11202106344S A SG11202106344S A SG 11202106344SA
Authority
SG
Singapore
Prior art keywords
patient
baseline
deutetrabenazine
score
study
Prior art date
Application number
SG11202106344SA
Other languages
English (en)
Inventor
Juha-Matti Savola
Mark Forrest Gordon
Frank Schneider
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of SG11202106344SA publication Critical patent/SG11202106344SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202106344SA 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy SG11202106344SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US201962801450P 2019-02-05 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
SG11202106344SA true SG11202106344SA (en) 2021-07-29

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106344SA SG11202106344SA (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Country Status (15)

Country Link
US (3) US11324732B2 (enExample)
EP (1) EP3893876A1 (enExample)
JP (1) JP2022519007A (enExample)
KR (1) KR20210114946A (enExample)
CN (1) CN113395966A (enExample)
AU (1) AU2019395250A1 (enExample)
BR (1) BR112021011386A2 (enExample)
CA (1) CA3123393A1 (enExample)
CL (1) CL2021001554A1 (enExample)
IL (1) IL283920A (enExample)
MX (1) MX2021007063A (enExample)
SG (1) SG11202106344SA (enExample)
TW (1) TWI784220B (enExample)
WO (1) WO2020123900A1 (enExample)
ZA (1) ZA202104786B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
US20240197714A1 (en) * 2021-04-15 2024-06-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
JP2024514873A (ja) * 2021-04-15 2024-04-03 ニューロクライン バイオサイエンシーズ,インコーポレイテッド デューテトラベナジンおよびcyp2d6阻害剤の併用投与のための方法
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) * 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン

Also Published As

Publication number Publication date
BR112021011386A2 (pt) 2021-08-31
EP3893876A1 (en) 2021-10-20
JP2022519007A (ja) 2022-03-18
US11324732B2 (en) 2022-05-10
CA3123393A1 (en) 2020-06-18
ZA202104786B (en) 2023-12-20
CN113395966A (zh) 2021-09-14
TWI784220B (zh) 2022-11-21
KR20210114946A (ko) 2021-09-24
US20200188371A1 (en) 2020-06-18
MX2021007063A (es) 2021-12-10
IL283920A (en) 2021-07-29
WO2020123900A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
TW202034917A (zh) 2020-10-01
CL2021001554A1 (es) 2022-02-11
US20240082225A1 (en) 2024-03-14
AU2019395250A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
EP3280375A4 (en) Body massaging apparatus
IL283920A (en) Deuterobenzene for the treatment of dyskinetic cerebral palsy
PL3297628T3 (pl) Azasetron do stosowania w leczeniu niedosłuchu
EP3725273C0 (en) MOTION ASSISTANCE DEVICE
ZA201800869B (en) Continuous process for the treatment of wastewater
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
PL3423060T3 (pl) Imatynib do stosowania w leczeniu udaru mózgu
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
IL286533A (en) Compounds for use in the treatment of adcy5-related dyskinesia
HK40060052A (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201614453D0 (en) Dressing
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201613368D0 (en) Apparatus for facilitating the sexual act for people with disabilities
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders